title: ÐÐ»Ð¸ÑÐ½Ð¸Ðµ ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ° Ð¸ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð½Ð° ÑÐµÐ½Ð¸Ð½-Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð²ÑÑ ÑÐ¸ÑÑÐµÐ¼Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Influence of coronavirus and influenza virus on the human renin-angiotensin system
Creators: name: ÐÐ²Ð°Ð½Ð¾Ð²Ð°, ÐÐºÐ°ÑÐµÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½Ð¿ÑÐµÐ²ÑÐ°ÑÐ°ÑÑÐ¸Ð¹ ÑÐµÑÐ¼ÐµÐ½Ñ (ÐÐÐ¤)
Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½ II
Ð±ÑÐ°Ð´Ð¸ÐºÐ¸Ð½Ð¸Ð½
ÑÐµÐ½Ð¸Ð½-Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½-Ð°Ð»ÑÐ´Ð¾ÑÑÐµÑÐ¾Ð½Ð¾Ð²Ð°Ñ ÑÐ¸ÑÑÐµÐ¼Ð°
Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÑ ÐÐÐ¤
ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ½Ð°Ñ Ð¸Ð½ÑÐµÐºÑÐ¸Ñ
Ð³Ð¸Ð´ÑÐ¾Ð»Ð¸Ð·
angiotensin-converting enzyme (ÐCE)
angiotensin II
bradykinin
renin-angiotensin-aldosterone system
ÐCE inhibitors
coronavirus infection
hydrolysis

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð²Ð»Ð¸ÑÐ½Ð¸Ñ ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ° COVID-19 Ð¸ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð½Ð° ÑÐµÐ½Ð¸Ð½-Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð²ÑÑ ÑÐ¸ÑÑÐµÐ¼Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. Ð ÑÐ°Ð±Ð¾ÑÐµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð»Ð°ÑÑ ÑÐµÑÐ¼ÐµÐ½ÑÐ°ÑÐ¸Ð²Ð½Ð°Ñ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½Ð¿ÑÐµÐ²ÑÐ°ÑÐ°ÑÑÐµÐ³Ð¾ ÑÐµÑÐ¼ÐµÐ½ÑÐ° (ÐÐÐ¤) Ð¸ ÐºÐ°ÑÐ±Ð¾ÐºÑÐ¸Ð¿ÐµÐ¿ÑÐ¸Ð´Ð°Ð·Ñ-N, Ð²ÑÐ¾Ð´ÑÑÐ¸Ñ Ð² ÑÐµÐ½Ð¸Ð½-Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½Ð¾Ð²ÑÑ ÑÐ¸ÑÑÐµÐ¼Ñ, Ð² ÑÑÐ²Ð¾ÑÐ¾ÑÐºÐ°Ñ ÐºÑÐ¾Ð²Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ½Ð¾Ð¹ Ð¸ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð¾Ð¹ Ð¸Ð½ÑÐµÐºÑÐ¸ÑÐ¼Ð¸. Ð ÐºÐ°ÑÐµÑÑÐ²Ðµ ÑÑÐ±ÑÑÑÐ°ÑÐ° Ð´Ð»Ñ ÐÐÐ¤ Ð±ÑÐ» Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½ Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½ I, Ð´Ð»Ñ ÐºÐ°ÑÐ±Ð¾ÐºÑÐ¸Ð¿ÐµÐ¿ÑÐ¸Ð´Ð°Ð·Ñ-N â Ð±ÑÐ°Ð´Ð¸ÐºÐ¸Ð½Ð¸Ð½. ÐÐ·Ð²ÐµÑÑÐ½Ð¾, ÑÑÐ¾ Ð°Ð½Ð³Ð¸Ð¾ÑÐµÐ½Ð·Ð¸Ð½ II Ð¾Ð±Ð»Ð°Ð´Ð°ÐµÑ ÑÐ¾ÑÑÐ´Ð¾ÑÑÐ¶Ð¸Ð²Ð°ÑÑÐ¸Ð¼ Ð´ÐµÐ¹ÑÑÐ²Ð¸ÐµÐ¼, Ð° Ð±ÑÐ°Ð´Ð¸ÐºÐ¸Ð½Ð¸Ð½ ÑÐ¾ÑÑÐ´Ð¾ÑÐ°ÑÑÐ¸ÑÑÑÑÐ¸Ð¼ Ð´ÐµÐ¹ÑÑÐ²Ð¸ÐµÐ¼. Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼ Ð¾Ð½Ð¸ ÑÐ²Ð»ÑÑÑÑÑ ÑÑÐ°ÑÑÐ½Ð¸ÐºÐ°Ð¼Ð¸ ÑÐµÐ³ÑÐ»ÑÑÐ¸Ð¸ ÐºÑÐ¾Ð²ÑÐ½Ð¾Ð³Ð¾ Ð´Ð°Ð²Ð»ÐµÐ½Ð¸Ñ. ÐÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ¾Ð² ÐÐÐ¤ ÑÐ»ÑÑÑÐ°ÐµÑ Ð¸ÑÑÐ¾Ð´Ñ ÑÐµÑÐ´ÐµÑÐ½Ð¾-ÑÐ¾ÑÑÐ´Ð¸ÑÑÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹, Ð¾Ð´Ð½Ð°ÐºÐ¾ ÐµÑÑÑ Ð¾Ð¿Ð°ÑÐµÐ½Ð¸Ñ, ÑÑÐ¾ Ð¾Ð½Ð¸ Ð¼Ð¾Ð³ÑÑ ÑÑÑÐ´ÑÐ¸ÑÑ Ð¿ÑÐ¾Ð³Ð½Ð¾Ð· Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ½Ð¾Ð¹ Ð¸Ð½ÑÐµÐºÑÐ¸ÐµÐ¹. Ð¦Ð¸ÑÐ¾ÐºÐ¸Ð½Ð¾Ð²ÑÐ¹ ÑÑÐ¾ÑÐ¼, Ð²ÑÐ·Ð²Ð°Ð½Ð½ÑÐ¹ COVID-19, Ð¸ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð½Ð°Ñ Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ñ Ð ÐÐÐ¡ Ð¼Ð¾Ð³ÑÑ ÑÑÐ¸Ð»Ð¸ÑÑ Ð²Ð¾ÑÐ¿Ð°Ð»ÐµÐ½Ð¸Ðµ Ð² Ð»ÐµÐ³ÐºÐ¸Ñ Ð¸ Ð´ÑÑÐ³Ð¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ. Ð¡Ð»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÐ½Ð¾, ÑÑÑÐµÑÑÐ²ÑÐµÑ Ð¾ÑÑÑÐ°Ñ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼Ð¾ÑÑÑ Ð² ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐµ ÑÐµÐºÐ¾Ð¼ÐµÐ½Ð´Ð°ÑÐ¸Ð¹ Ð¿Ð¾ Ð¿ÑÐ¸Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ ÑÑÐ¸Ñ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð² Ð¿ÑÐ¸ Ð·Ð°ÑÐ°Ð¶ÐµÐ½Ð¸Ð¸ SARS-COV-2. Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð¸Ð·Ð¼ÐµÑÐµÐ½Ð¸Ñ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð¸ÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¼ÐµÑÐ¾Ð´Ð° Ð¼Ð°ÑÑ-ÑÐ¿ÐµÐºÑÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð°. ÐÑÐ»Ð¸ Ð¿Ð¾Ð´Ð¾Ð±ÑÐ°Ð½Ñ Ð¾Ð¿ÑÐ¸Ð¼Ð°Ð»ÑÐ½ÑÐµ ÑÑÐ»Ð¾Ð²Ð¸Ñ Ð´Ð»Ñ Ð¾ÑÐµÐ½ÐºÐ¸ Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð²ÑÐ¸ÑÑÑ Ð² ÑÐ¾Ð´Ðµ Ð³Ð¸Ð´ÑÐ¾Ð»Ð¸Ð·Ð° Ð¿ÐµÐ¿ÑÐ¸Ð´Ð¾Ð². ÐÑÐ»Ð¸ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ¸Ñ Ð¼ÐµÐ¶Ð´Ñ ÑÑÐµÐ¼Ñ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐ¼Ð¸ Ð³ÑÑÐ¿Ð¿Ð°Ð¼Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², ÑÑÐ¾ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÐµÑ Ð¾ Ð²Ð»Ð¸ÑÐ½Ð¸Ð¸ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ Ð½Ð° Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ ÐÐÐ¤. Ð¢Ð°ÐºÐ¶Ðµ Ð±ÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ ÐºÐ¾ÑÐ¾Ð½Ð°Ð²Ð¸ÑÑÑÐ½Ð°Ñ Ð¸Ð½ÑÐµÐºÑÐ¸Ñ Ð²Ð»Ð¸ÑÐµÑ Ð½Ð° Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ ÐºÐ°ÑÐ±Ð¾ÐºÑÐ¸Ð¿ÐµÐ¿ÑÐ¸Ð´Ð°Ð·Ñ N.
description: This work is devoted to the influence of the coronavirus COVID-19 and the influenza virus on the human renin-angiotensin system. The work investigated the enzymatic activity of angiotensin-converting enzyme (ACE) and carboxypeptidase-N, included in the renin-angiotensin system, in the blood serum of patients with coronavirus and influenza infections. Angiotensin I was used as a substrate for ACE, and bradykinin for carboxypeptidase-N. It is known that angiotensin II has a vasoconstrictor effect, and bradykinin has a vasodilator effect. Thus, they are involved in the regulation of blood pressure. The use of ACE inhibitors improves the outcomes of cardiovascular disease, but there are concerns that they may worsen the prognosis of patients with coronavirus infection. The cytokine storm caused by COVID-19 and increased RAAS activation can increase inflammation in the lungs and other organs. Therefore, there is an urgent need to develop recommendations for the use of these drugs when infected with SARS-COV-2. In this work, measurements were carried out using the method of mass spectrometric analysis. Optimal conditions were selected for assessing the peptides formed during hydrolysis. Differences were found between the three study groups of patients, which indicates the effect of the disease on ACE activity. It was also found that coronavirus infection affects the activity of carboxypeptidase N.